Clinical Development Clinical Trials HR Protein 
The Pharma Data
JULY 22, 2021
(NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The companies will equally share worldwide development costs, commercialization expenses, and profits. Chief Executive Officer at Arvinas.
Drug Discovery World
MARCH 24, 2023
Efti As a first-in-class soluble LAG-3 protein targeting MHC Class II ligands on antigen-presenting cells (APC), efti is positioned to improve clinical outcomes from standard-of-care chemotherapy. Its activation of APCs (e.g., The first patient is expected to be enrolled early in the second quarter of the 2023 calendar year.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 14, 2021
“The FIGHT trial results demonstrate that treatment with bemarituzumab in combination with chemotherapy can deliver a significant reduction in the risk of disease progression and death in gastric cancer patients whose tumors overexpress FGFR2b.”. HR (95% CI): 0.68. HR (95% CI): 0.54 (0.33, 0.87).
XTalks
DECEMBER 4, 2020
Recently, Medpace hosted an informative webinar on CKD and how new developments in our understanding of the disease are helping to shape more effective clinical research programs. Watch this free webinar to learn more about CKD from Medpace’s medical and clinical operations experts. Developed in 1999 2.
The Pharma Data
DECEMBER 29, 2020
NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. Evaluation of its safety and efficacy is ongoing in multiple clinical trials. In the U.S.
The Pharma Data
MARCH 17, 2021
The data builds on the primary outcome analysis of the positive Phase 3 monarchE trial that previously showed Verzenio, in combination with ET, decreased the risk of breast cancer recurrence by 28.7 High risk was specifically defined as women (any menopausal status) and men with resected HR+, HER2- invasive early breast cancer with either ?4
The Pharma Data
AUGUST 30, 2021
“We are pleased to offer two potential new treatment options with KEYTRUDA for patients in Japan based on compelling data from our clinical trial program,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. months (95% CI, 7.6-11.3)
Expert insights. Personalized for you.
52 
Let's personalize your content